Matches in SemOpenAlex for { <https://semopenalex.org/work/W1774029313> ?p ?o ?g. }
- W1774029313 endingPage "12908" @default.
- W1774029313 startingPage "12890" @default.
- W1774029313 abstract "// Fanny Le Du 1, 2 , Bedrich L. Eckhardt 1 , Bora Lim 1, 6 , Jennifer K. Litton 1, 3, 6 , Stacy Moulder 1, 6 , Funda Meric-Bernstam 4, 6 , Ana M. Gonzalez-Angulo 1, 5, 6 , Naoto T. Ueno 1, 6 1 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Department of Medical Oncology, Eugène Marquis Cancer Center, Rennes, France 3 Clinical Cancer Genetics Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, USA 4 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 5 Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 6 The University of Texas MD Anderson Women’s Cancer Moons Shot Program, Houston, TX, USA Correspondence to: Naoto T. Ueno, e-mail: nueno@mdanderson.org Keywords: triple-negative breast cancer, gene expression profiling, epithelial-mesenchymal transition, immunotherapy, targeted therapy Received: February 17, 2015 Accepted: April 24, 2015 Published: May 07, 2015 ABSTRACT Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC). We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development. With the ultimate aim to streamline translational medicine, we linked these categories of TNBC according to their gene-expression signatures, biological function, and clinical outcome. To this end, we define five potential clinically actionable groupings of TNBC: 1) basal-like TNBC with DNA-repair deficiency or growth factor pathways; 2) mesenchymal-like TNBC with epithelial-to-mesenchymal transition and cancer stem cell features; 3) immune-associated TNBC; 4) luminal/apocrine TNBC with androgen-receptor overexpression; and 5) HER2-enriched TNBC. For each defined subtype, we highlight the major biological pathways and discuss potential targeted therapies in TNBC that might abrogate disease progression. However, many of these potential targets need clinical validation by clinical trials. We have yet to know how we can enrich the targets by molecular classifications." @default.
- W1774029313 created "2016-06-24" @default.
- W1774029313 creator A5007218333 @default.
- W1774029313 creator A5014713051 @default.
- W1774029313 creator A5042271475 @default.
- W1774029313 creator A5048206365 @default.
- W1774029313 creator A5053893309 @default.
- W1774029313 creator A5073488441 @default.
- W1774029313 creator A5076426660 @default.
- W1774029313 creator A5088814426 @default.
- W1774029313 date "2015-05-07" @default.
- W1774029313 modified "2023-10-02" @default.
- W1774029313 title "Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?" @default.
- W1774029313 cites W1517573550 @default.
- W1774029313 cites W1523531555 @default.
- W1774029313 cites W1542978301 @default.
- W1774029313 cites W1979958627 @default.
- W1774029313 cites W1984365236 @default.
- W1774029313 cites W1985516002 @default.
- W1774029313 cites W1986757639 @default.
- W1774029313 cites W1988055795 @default.
- W1774029313 cites W1995224853 @default.
- W1774029313 cites W2005303413 @default.
- W1774029313 cites W2007058211 @default.
- W1774029313 cites W2014331129 @default.
- W1774029313 cites W2031770999 @default.
- W1774029313 cites W2044702943 @default.
- W1774029313 cites W2055498399 @default.
- W1774029313 cites W2059567292 @default.
- W1774029313 cites W2063813632 @default.
- W1774029313 cites W2076583198 @default.
- W1774029313 cites W2079207159 @default.
- W1774029313 cites W2080661875 @default.
- W1774029313 cites W2086064725 @default.
- W1774029313 cites W2093716073 @default.
- W1774029313 cites W2095646155 @default.
- W1774029313 cites W2095933146 @default.
- W1774029313 cites W2096283457 @default.
- W1774029313 cites W2098276344 @default.
- W1774029313 cites W2098320019 @default.
- W1774029313 cites W2098804778 @default.
- W1774029313 cites W2099335989 @default.
- W1774029313 cites W2100413206 @default.
- W1774029313 cites W2104024752 @default.
- W1774029313 cites W2106292881 @default.
- W1774029313 cites W2107617686 @default.
- W1774029313 cites W2109600717 @default.
- W1774029313 cites W2110017381 @default.
- W1774029313 cites W2111393163 @default.
- W1774029313 cites W2113113178 @default.
- W1774029313 cites W2113370608 @default.
- W1774029313 cites W2114505219 @default.
- W1774029313 cites W2116236442 @default.
- W1774029313 cites W2118934356 @default.
- W1774029313 cites W2120656656 @default.
- W1774029313 cites W2120859657 @default.
- W1774029313 cites W2124640147 @default.
- W1774029313 cites W2125154434 @default.
- W1774029313 cites W2125885282 @default.
- W1774029313 cites W2127967682 @default.
- W1774029313 cites W2129643153 @default.
- W1774029313 cites W2130084494 @default.
- W1774029313 cites W2131994307 @default.
- W1774029313 cites W2134539328 @default.
- W1774029313 cites W2136652669 @default.
- W1774029313 cites W2139517025 @default.
- W1774029313 cites W2142486051 @default.
- W1774029313 cites W2142641092 @default.
- W1774029313 cites W2142658272 @default.
- W1774029313 cites W2142739240 @default.
- W1774029313 cites W2144092647 @default.
- W1774029313 cites W2146267790 @default.
- W1774029313 cites W2147154862 @default.
- W1774029313 cites W2147343434 @default.
- W1774029313 cites W2148678536 @default.
- W1774029313 cites W2148823465 @default.
- W1774029313 cites W2149173771 @default.
- W1774029313 cites W2153206149 @default.
- W1774029313 cites W2153769134 @default.
- W1774029313 cites W2154142993 @default.
- W1774029313 cites W2154453972 @default.
- W1774029313 cites W2156769579 @default.
- W1774029313 cites W2157058802 @default.
- W1774029313 cites W2158501247 @default.
- W1774029313 cites W2159274850 @default.
- W1774029313 cites W2160834915 @default.
- W1774029313 cites W2161861008 @default.
- W1774029313 cites W2164237749 @default.
- W1774029313 cites W2165104644 @default.
- W1774029313 cites W2165404212 @default.
- W1774029313 cites W2165936545 @default.
- W1774029313 cites W2169360530 @default.
- W1774029313 cites W2171972386 @default.
- W1774029313 cites W238691276 @default.
- W1774029313 cites W2560367415 @default.
- W1774029313 cites W3093265161 @default.
- W1774029313 cites W4243731138 @default.
- W1774029313 doi "https://doi.org/10.18632/oncotarget.3849" @default.